Difference between revisions of "Mycophenolate mofetil (CellCept)"
Jump to navigation
Jump to search
m |
|||
| (18 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Immunosuppressive medication, inhibits inosine monophosphate dehydrogenase (IMPDH). Mycophenolate mofetil is converted in vivo to the active agent mycophenolic acid (MPA), which is a reversible, selective, and non-competitive inhibitor of inosine monophosphate dehydrogenase (IMPDH). MPA results in the inhibition of the de novo synthesis of guanosine, which T and B-cells are dependent upon for proliferation (as opposed to other cell types, which can use salvage pathways). MPA has a cytostatic effect on lymphocytes, suppresses antibody formation by B-cells, and inhibits T and B-cell proliferative response to mitogenic and allospecific stimuli. MPA also inhibits glycosylation of glycoproteins that play a role in intercellular adhesion to endothelial cells, which may suppress localization of leukocytes to areas of inflammation or graft rejection.<ref name="insert">[https://www.gene.com/download/pdf/cellcept_prescribing.pdf Mycophenolate mofetil (CellCept) package insert]</ref><ref>[[ | + | Class/mechanism: Immunosuppressive medication, inhibits inosine monophosphate dehydrogenase (IMPDH). Mycophenolate mofetil is converted in vivo to the active agent mycophenolic acid (MPA), which is a reversible, selective, and non-competitive inhibitor of inosine monophosphate dehydrogenase (IMPDH). MPA results in the inhibition of the de novo synthesis of guanosine, which T and B-cells are dependent upon for proliferation (as opposed to other cell types, which can use salvage pathways). MPA has a cytostatic effect on lymphocytes, suppresses antibody formation by B-cells, and inhibits T and B-cell proliferative response to mitogenic and allospecific stimuli. MPA also inhibits glycosylation of glycoproteins that play a role in intercellular adhesion to endothelial cells, which may suppress localization of leukocytes to areas of inflammation or graft rejection.<ref name="insert">[https://www.gene.com/download/pdf/cellcept_prescribing.pdf Mycophenolate mofetil (CellCept) package insert]</ref><ref>[[:File:Mycophenolate.pdf | Mycophenolate mofetil (CellCept) package insert (locally hosted backup)]]</ref><ref>[http://www.cellcept.com Cellcept manufacturer's website]</ref> |
<br>Route: PO, IV | <br>Route: PO, IV | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> |
| + | |||
| + | ==Toxicity management== | ||
| + | *[https://www.mycophenolaterems.com/#Main Link to REMS program] | ||
==Disease for which it is used== | ==Disease for which it is used== | ||
| − | *[[ | + | *[[Graft versus host disease]] |
| + | *[[Immune thrombocytopenia]] | ||
==Patient drug information== | ==Patient drug information== | ||
| Line 14: | Line 18: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * | + | *1995-05-03: Initial FDA approval |
| + | ==History of changes in EMA indication== | ||
| + | *1996-02-14: Initial authorization | ||
| + | ==History of changes in PMDA indication== | ||
| + | *2021-06-25: New indication and a new dosage for the suppression of [[Graft versus host disease|graft-versus-host disease in hematopoietic stem cell transplantation]]. | ||
| + | ==Also known as== | ||
| + | *'''Brand name:''' CellCept, Myclausen, Myfenex | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| − | [[Category: | + | [[Category:Drugs]] |
| − | [[Category: | + | [[Category:Oral medications]] |
| − | [[Category:Immune | + | [[Category:Intravenous medications]] |
| − | [[Category: | + | [[Category:IMPDH inhibitors]] |
| + | |||
| + | [[Category:Graft versus host disease medications]] | ||
| + | [[Category:Immune thrombocytopenia medications]] | ||
| + | |||
| + | [[Category:REMS program]] | ||
| + | [[Category:FDA approved in 1995]] | ||
| + | [[Category:EMA approved in 1996]] | ||
Latest revision as of 09:35, 1 July 2023
General information
Class/mechanism: Immunosuppressive medication, inhibits inosine monophosphate dehydrogenase (IMPDH). Mycophenolate mofetil is converted in vivo to the active agent mycophenolic acid (MPA), which is a reversible, selective, and non-competitive inhibitor of inosine monophosphate dehydrogenase (IMPDH). MPA results in the inhibition of the de novo synthesis of guanosine, which T and B-cells are dependent upon for proliferation (as opposed to other cell types, which can use salvage pathways). MPA has a cytostatic effect on lymphocytes, suppresses antibody formation by B-cells, and inhibits T and B-cell proliferative response to mitogenic and allospecific stimuli. MPA also inhibits glycosylation of glycoproteins that play a role in intercellular adhesion to endothelial cells, which may suppress localization of leukocytes to areas of inflammation or graft rejection.[1][2][3]
Route: PO, IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Toxicity management
Disease for which it is used
Patient drug information
- Mycophenolate mofetil (CellCept) package insert[1]
- Mycophenolate mofetil (CellCept) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 1995-05-03: Initial FDA approval
History of changes in EMA indication
- 1996-02-14: Initial authorization
History of changes in PMDA indication
- 2021-06-25: New indication and a new dosage for the suppression of graft-versus-host disease in hematopoietic stem cell transplantation.
Also known as
- Brand name: CellCept, Myclausen, Myfenex